(NCT03212274) In a randomized phase 2 trial, olaparib and cediranib combination was evaluated by comparing it to bevacizumab in patients with recurrent GBM who had not previously received vascular endothelial growth factor (VEGF) therapy. Here, VEGFA is linked to glioblastoma.